Revvity (NYSE:RVTY) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Revvity (NYSE:RVTY) announced its quarterly earnings data on Monday. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.04, RTT News reports. The firm had revenue of $649.90 million for the quarter, compared to the consensus estimate of $646.83 million. Revvity had a net margin of 5.49% and a return on equity of 7.37%. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. Revvity updated its FY24 guidance to 4.55-4.75 EPS.

Revvity Stock Performance

Revvity stock opened at $102.60 on Thursday. The business has a 50 day moving average of $104.70 and a 200-day moving average of $101.32. The company has a market capitalization of $12.67 billion, a P/E ratio of 84.79, a P/E/G ratio of 2.67 and a beta of 1.09. Revvity has a 1 year low of $79.50 and a 1 year high of $132.54. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.23 and a quick ratio of 1.77.

Revvity Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Friday, July 19th. Revvity’s dividend payout ratio (DPR) is currently 23.14%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RVTY. KeyCorp increased their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. UBS Group downgraded Revvity from a “buy” rating to a “neutral” rating and raised their target price for the company from $105.00 to $125.00 in a report on Tuesday, January 16th. TD Cowen lifted their price target on Revvity from $123.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus upped their price objective on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Finally, Raymond James raised their price objective on Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Insider Buying and Selling

In related news, insider Prahlad R. Singh sold 21,217 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the sale, the insider now owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.60% of the stock is owned by corporate insiders.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.